Catheter ablation to treat supraventricular tachycardia (SVT) is not detrimental to patients

NewsGuard 100/100 Score

A recent study published in Pacing and Clinical Electrophysiology (PACE) determined that the use of catheter ablation to treat supraventricular tachycardia (SVT) is not detrimental to patients.

This data refutes previous evidence which suggested a high incidence of injury to a patient's cardiac nerves, possibly resulting in accelerated heart rates following the procedure.

This research, supported in part by the National Institute of Health and led by Steven M. Markowitz at The New York Hospital-Cornell Medical Center assessed the function of cardiac nerves in patients undergoing catheter ablation with radiofrequency energy. It was determined that no significant injury occurs to cardiac nerves as a result of ablation, and changes in heart rate during the procedure are transitory and are related primarily to medications and other procedural variables.

Catheter ablation has become a standard therapy for SVT which is an arrhythmia, or abnormal heart rhythm including such specific conditions as atrial fibrillation, AV nodal re-entrant tachycardia, and Wolff-Parkinson-White syndrome.

http://www.blackwellpublishing.com

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Notre Dame study identifies high-risk population for CAUTIs due to fibrinolytic deficiencies